Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This commentary discusses how recent shifts in prostate cancer screening and management may render 5-alpha reductase inhibitors irrelevant for chemoprevention, despite evidence of their long-term safety and effectiveness in preventing low-grade prostate cancer.

This source reports that in men treated with 5α-reductase inhibitors for androgenetic alopecia, sexual adverse events such as decreased libido and erectile dysfunction occurred at rates from 1.9% to 12% in clinical trials, with effects often being mild and reversible upon stopping treatment.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.

In this study, dermatologists from the Spanish Hair and Nail Disorders Group viewed post-finasteride syndrome as rare and primarily of psychiatric origin, with limited scientific evidence supporting its existence.

This study found that the 4Kscore model, when adjusted for kallikrein marker changes due to finasteride use, improved the prediction of high-grade prostate cancer compared to adjusted total PSA alone in men taking 5-α-reductase inhibitors.

This meta-analysis reports that 5-alpha-reductase inhibitors are associated with a 31% increased risk of depression, with varying outcomes depending on the comparator group, highlighting significant heterogeneity across studies.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

In this case report, the researchers documented two instances of melasma linked to finasteride use, highlighting the need for clinicians to review medication history when treating facial hyperpigmentation, especially in individuals with darker skin types.

This paper reports two cases of finasteride-induced melasma, expanding the limited literature on this side effect, and underscores the importance of considering 5-ARI exposure in patients with new or persistent hyperpigmentation, especially among those with darker skin.

In this study, network meta-analyses were used to explore the ranking of various 5-alpha reductase inhibitor regimens on reducing dihydrotestosterone levels and to investigate whether this reduction correlates with increased total hair density in male androgenetic alopecia.

Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.

This study reports that using 5-alpha reductase inhibitors is associated with a 31% increased risk of depression, highlighting that the choice of comparator group significantly affects study results.

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

This study found a complex relationship between cumulative doses of 5-ARIs and all-cause mortality among BPH or AGA patients, with lower doses linked to higher suicide rates and higher doses reducing cardiovascular mortality risk.

This nested case-control study observed that patients with benign prostatic hyperplasia or androgenic alopecia who had a cumulative 5-ARI dose exceeding 5840 defined daily doses had a significantly reduced mortality risk, while lower doses were linked to higher mortality and suicide rates.

In this systematic review and meta-analysis, the authors found no statistically significant association between the use of 5α-reductase inhibitors and the risk of depression or suicide among over two million studied patients.

In this research review, the authors note that while topical minoxidil and oral finasteride are FDA-approved treatments for male androgenetic alopecia, some patients experience inadequate responses or side effects, prompting exploration of alternative therapies like newer 5-α reductase inhibitors and androgen receptor antagonists.

This research highlights that while minoxidil and 5-alpha reductase inhibitors are commonly used for treating pattern hair loss, there is limited evidence supporting their relative effectiveness in women compared to men.

This Swedish cohort study found no association between the use of anti-androgenic 5α-reductase inhibitors and improved 5-year all-cause or disease-specific mortality in oesophago-gastric cancer patients, challenging the hypothesis that these drugs enhance survival outcomes.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This case report observed that hypogonadism and cold sensation resolved in a patient after discontinuing 5-alpha-reductase inhibitors, suggesting these medications may contribute to such symptoms.

Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

5-ARI therapy may help prevent prostate cancer progression.

This study found that men using 5-alpha-reductase inhibitors showed an increased risk for dementia shortly after starting treatment, which diminished over time, and a consistent association with depression, but no link to suicide.

Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.